Table Info

Table 1.

Main trials including ARIs for PC treatment

Drug	Patient stage	Study	Benefit
Enzalutamide	mCRPCa post-CT	AFFIRM 2012	+ OS
Enzalutamide	mCRPCa before-CT	PREVAIL 2014	+ PFS
Enzalutamide	mHSPCa	ENZAMET 2019	+ OS
Enzalutamide	mHSPCa	ARCHES 2019	+ OS
Enzalutamide	nmCRPCa, PSADT ≤ 10 ms	PROSPER 2018	+ OS
Enzalutamide	nmHSPCa, PSADT ≤ 9 ms	EMBARK 2020	+ MFS
Apalutamide	nmCRPCa, PSADT ≤ 10 ms	SPARTAN 2018	+ MFS
Apalutamide	mHSPCa	TITAN 2019	+ OS
Darolutamide	nmCRPCa, PSADT ≤ 10 ms	ARAMIS 2019	+ OS
Darolutamide	mHSPC	ARASENS 2022	+ OS

CT: computed tomography; +: increasing benefit; mHSPC: metastatic hormone sensitive prostate cancer

Declarations

Acknowledgments

We thank Giovanni Campodonico for providing graphic technical support.

Author contributions

FC: Conceptualization, Data curation, Writing—original draft, Writing—review & editing. LF: Conceptualization, Writing—original draft, Writing—review & editing. VC: Resources, Visualization. CI: Supervision, Validation.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

References

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. [DOI] [PubMed]

Huggins C, Clark PJ. Quantitative studies of prostatic secretion : II. The effect of castration and of estrogen injection on the normal and on the hyperplastic prostate glands of dogs. J Exp Med. 1940;72:747–62. [DOI] [PubMed] [PMC]

Lodde M, Lacombe L, Fradet Y. Salvage therapy with bicalutamide 150 mg in nonmetastatic castration-resistant prostate cancer. Urology. 2010;76:1189–93. [DOI] [PubMed]

de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al.; COU-AA-301 Investigators. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995–2005. [DOI] [PubMed] [PMC]

Fizazi K, Azad AA, Matsubara N, Carles J, Fay AP, De Giorgi U, et al. First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nat Med. 2024;30:257–64. Erratum in: Nat Med. 2024;30:1505. [DOI] [PubMed] [PMC]

Crawford ED, Schellhammer PF, McLeod DG, Moul JW, Higano CS, Shore N, et al. Androgen receptor targeted treatments of prostate cancer: 35 years of progress with antiandrogens. J Urol. 2018;200:956–66. [DOI] [PubMed]

Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009;324:787–90. [DOI] [PubMed] [PMC]

Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al.; AFFIRM Investigators. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187–97. [DOI] [PubMed]

Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al.; PREVAIL Investigators. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424–33. [DOI] [PubMed] [PMC]

10.

Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2019;37:2974–86. [DOI] [PubMed] [PMC]

11.

Armstrong AJ, Azad AA, Iguchi T, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, et al. Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2022;40:1616–22. [DOI] [PubMed] [PMC]

12.

Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, et al.; ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. 2019;381:121–31. [DOI] [PubMed]

13.

Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2018;378:2465–74. [DOI] [PubMed] [PMC]

14.

Sternberg CN, Fizazi K, Saad F, Shore ND, De Giorgi U, Penson DF, et al.; PROSPER Investigators. Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2020;382:2197–206. [DOI] [PubMed]

15.

Freedland SJ, De Giorgi U, Gleave M, Rosbrook B, Shen Q, Sugg J, et al. A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study design. BMJ Open. 2021;11:e046588. [DOI] [PubMed] [PMC]

16.

Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med. 2018;378:1408–18. [DOI] [PubMed]

17.

Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, et al.; TITAN Investigators. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med. 2019;381:13–24. [DOI] [PubMed]

18.

Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, et al.; ARAMIS Investigators. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2019;380:1235–46. Erratum in: N Engl J Med. 2022;387:860. [DOI] [PubMed]

19.

Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, et al.; ARASENS Trial Investigators. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med. 2022;386:1132–42. [DOI] [PubMed] [PMC]

20.

Ferrari AC, Alumkal JJ, Stein MN, Taplin ME, Babb J, Barnett ES, et al. Epigenetic therapy with panobinostat combined with bicalutamide rechallenge in castration-resistant prostate cancer. Clin Cancer Res. 2019;25:52–63. Erratum in: Clin Cancer Res. 2019;25:2672. [DOI] [PubMed]

21.

A clinical study evaluating the benefit of adding rucaparib to enzalutamide for men with metastatic prostate cancer that has become resistant to testosterone-deprivation therapy (CASPAR) [Internet]. Source: National Library of Medicine; [cited 2023 Dec 28]. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT04455750

22.

Hadfield MJ, Lyall V, Holle LM, Dennison M. Updates in the treatment of non-metastatic castrate-resistant prostate cancer: the benefit of second-generation androgen receptor antagonists. Ann Pharmacother. 2023;57:1302–11. [DOI] [PubMed]

23.

Ng CT, Bonilla HMG, Bryce AH, Singh P, Herrmann J. Approaches to prevent and manage cardiovascular disease in patients receiving therapy for prostate cancer. Curr Cardiol Rep. 2023;25:889–99. [DOI] [PubMed] [PMC]

24.

Hoy SM. Apalutamide: a review in metastatic castration-sensitive prostate cancer. Drugs. 2020;80:1579–85. [DOI] [PubMed]

25.

Patel UJ, Caulfield S. Apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer. J Adv Pract Oncol. 2019;10:501–7. [DOI] [PubMed] [PMC]

26.

Tripathy S. The ARAMIS trial: why darolutamide is better than apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer. Indian J Urol. 2021;37:293–4. [DOI] [PubMed] [PMC]

27.

Cattrini C, Caffo O, De Giorgi U, Mennitto A, Gennari A, Olmos D, et al. Apalutamide, darolutamide and enzalutamide for nonmetastatic castration-resistant prostate cancer (nmCRPC): a critical review. Cancers (Basel). 2022;14:1792. [DOI] [PubMed] [PMC]

28.

Shore N, Garcia-Horton V, Terasawa E, Ayyagari R, Grossman JP, Waldeck AR. Safety differences across androgen receptor inhibitors in nonmetastatic castration-resistant prostate cancer. Future Oncol. 2023;19:385–95. [DOI] [PubMed]